# Febrile Infant Workup

Evaluate well-appearing febrile infants by age, urinalysis, blood culture, and inflammatory markers; reserve lumbar puncture, empiric antibiotics, and hospitalization for higher-risk profiles while preserving reliable follow-up for selected older low-risk infants.

**Clinical question:** How should U.S. clinicians evaluate and disposition a well-appearing febrile infant using age, urine testing, cultures, and inflammatory markers?

Updated: 2026-09-15T22:22:11.099653+00:00

## What matters in practice
- Apply the AAP-oriented pathway only to well-appearing, term infants aged 8 to 60 days with fever and no apparent source; preterm infants are excluded from the guideline population. [15]
- Obtain urine testing because UTI is the most frequent bacterial infection in well-appearing febrile infants younger than 60 days, occurring in approximately 5% to 17%. [15]
- For infants aged 22 to 60 days, normal urinalysis plus reassuring inflammatory markers identifies a substantially lower-risk group in whom lumbar puncture, empiric antibiotics, and hospitalization may be avoidable. [5][14]
- When procalcitonin is unavailable, use the combined abnormal-marker thresholds of temperature greater than 38.5°C, ANC greater than 5,200/mm3, and CRP 20 mg/L or greater rather than any marker alone. [14][20]
- A positive respiratory viral test, including SARS-CoV-2, lowers but does not eliminate UTI and invasive bacterial infection risk; it should not replace age-based urine and bacterial evaluation. [1][2][21]

## Identify infants who require a full sepsis-directed evaluation

Age and appearance determine whether risk stratification is appropriate.

Use age-specific risk stratification only after confirming that the infant is well appearing and has fever without an apparent source. The 2021 AAP clinical practice guideline applies to term infants born at 37 weeks' gestation or later who are 8 to 60 days old; preterm infants are outside that guideline population and require individualized evaluation. [15]

Do not downgrade a documented home fever simply because the infant is afebrile in the emergency department. Infants with reported fever at home have a non-negligible UTI risk and a similar invasive bacterial infection prevalence compared with infants febrile on presentation; manage them with the same age-based pathway. [21]

Separate invasive bacterial infection from UTI when making procedural and disposition decisions. Among well-appearing febrile infants younger than 60 days, reported rates are approximately 5% to 17% for UTI, 1% to 2% for bacteremia, and 0.2% to 1% for meningitis. [15]
- Do not apply low-risk outpatient pathways to an infant who is not well appearing or who falls outside the studied gestational-age population. [15]
- Treat a rectal temperature of 38.0°C or higher documented at home or in clinical care as a fever requiring the same evaluation framework. [7][21]

*Population boundaries that change use of the standard febrile-infant pathway. [15][21]*

| Clinical feature | Workup implication |
| --- | --- |
| Well appearing, term, 8-60 days, no source | Use age-stratified urine, blood, inflammatory-marker, and cerebrospinal-fluid decisions. [15] |
| Preterm birth | AAP pathway does not apply; individualize evaluation because the evidence base was derived primarily in term infants. [15] |
| Fever measured only at home | Use the same approach as for fever measured in the emergency department. [21] |
| Ill appearance | Do not use low-risk outpatient criteria; pursue urgent evaluation for bacteremia and meningitis. [5][15] |

## Obtain urine testing and age-appropriate blood evaluation

Urine results and inflammatory markers drive the next procedural decision.

Obtain urinalysis and urine culture as the foundational bacterial assessment because UTI is the dominant serious bacterial infection in this population. A normal urinalysis is a key component of low-risk classification; leukocytes on dipstick or leukocyturia moves the infant out of low-risk pathways used for outpatient management. [6][22]

For infants being evaluated for invasive bacterial infection, obtain a CBC with ANC, blood culture, and inflammatory markers. Modern prediction strategies use urine and blood testing to identify infants aged 22 to 60 days at substantially lower risk for bacteremia and bacterial meningitis, but risk is not zero even when screening results are normal. [5][14]

Use procalcitonin preferentially when available because it has better discrimination for invasive bacterial infection than CRP, WBC count, or ANC in young febrile infants. Published low-risk procalcitonin cutoffs vary from 0.12 to 1.71 ng/mL; therefore, interpret the value within a validated institutional pathway rather than substituting an arbitrary standalone threshold. [19]
- A procalcitonin less than 0.5 ng/mL was part of a prospective low-risk outpatient rule for infants older than 21 days, together with well appearance, absent urine leukocytes, ANC 10,000/mm3 or less, CRP 20 mg/L or less, and no deterioration during emergency observation. [22]
- Recent antibiotic exposure is a major evidence gap: published prediction-rule studies generally excluded or underrepresented these infants, so standard marker cutoffs cannot be assumed to perform equivalently. [20]

### When procalcitonin is unavailable

Use the AAP-recommended combination of maximum temperature, ANC, and CRP. Abnormal values are temperature greater than 38.5°C, ANC greater than 5,200/mm3, and CRP 20 mg/L or greater. In a single-center evaluation, the low-risk combination of temperature 38.5°C or lower, ANC 5,200/mm3 or lower, and CRP 20 mg/L or lower had 100% sensitivity for invasive bacterial infection, with 46% specificity. [14][20]
- Do not use temperature, ANC, or CRP in isolation to designate an infant low risk when procalcitonin is unavailable. [14][20]
- ANC 4,000/mm3 or lower is an alternative threshold discussed in AAP-oriented risk stratification, but the 5,200/mm3 cutoff classified more infants as low risk while retaining high sensitivity in the cited cohort. [14]

*Inflammatory-marker approaches for febrile infants 8 to 60 days. [14][19][20]*

| Testing context | Reassuring pattern | Result that changes management |
| --- | --- | --- |
| Procalcitonin available | Use a validated pathway that incorporates procalcitonin with urine and other clinical criteria; no single universal low-risk cutoff is established. [19] | Elevated procalcitonin or a nonreassuring urine result should prompt higher-risk evaluation rather than outpatient designation. [19][22] |
| Procalcitonin unavailable | Temperature 38.5°C or lower, ANC 5,200/mm3 or lower, and CRP 20 mg/L or lower. [14][20] | Temperature greater than 38.5°C, ANC greater than 5,200/mm3, or CRP 20 mg/L or greater is abnormal and should remove the infant from the reassuring-marker group. [14][20] |
| Recent antibiotics | No validated reassuring marker combination. [20] | Do not rely on standard prediction-rule cutoffs alone. [20] |

## Use age and risk markers to decide on cerebrospinal fluid testing

The central tradeoff is avoiding unnecessary lumbar puncture without missing meningitis.

For the youngest eligible infants, maintain a low threshold for lumbar puncture because invasive bacterial infection risk declines over the first weeks of life and evidence-based risk stratification is most useful in older infants. The outpatient literature does not recommend outpatient management for infants younger than 28 days, whereas selected infants older than 21 days have been studied after short emergency observation. [13][22]

For infants aged 29 to 60 days, a normal urinalysis and normal blood-based risk assessment identify a group at substantially lower risk of invasive bacterial infection in whom lumbar puncture, empiric antibiotics, and hospitalization may be avoided when follow-up is reliable. This is a risk-reduction strategy, not proof that bacterial meningitis is impossible. [5][14]

An abnormal urinalysis does not by itself establish meningitis, but it prevents simple designation as a low-risk febrile infant. Pair the urine result with blood culture and inflammatory markers when deciding whether cerebrospinal fluid testing and parenteral treatment are warranted. [5][22]
- Escalate to lumbar puncture when an infant is not well appearing or has nonreassuring blood or urine screening, rather than relying on a viral test to defer invasive evaluation. [1][2][5]
- If fever began less than 6 hours before presentation, recognize that a normal initial urinalysis and biomarkers may precede abnormal findings; observation or a lower threshold for escalation is reasonable. [4]

*Risk features that support escalation beyond screening tests. [4][5][13][22]*

| Finding | Interpretation | Next action |
| --- | --- | --- |
| Age younger than 28 days | Outpatient management is not recommended in the cited older outpatient framework. [13] | Perform hospital-based evaluation rather than using older-infant outpatient criteria. [13] |
| Normal urinalysis and reassuring blood testing at 29-60 days | Substantially lower invasive bacterial infection risk, but not zero. [5][14] | Consider deferring lumbar puncture only within an age-specific pathway and with reliable follow-up. [5] |
| Abnormal urinalysis or inflammatory marker | No longer fits reassuring low-risk profile. [14][22] | Escalate bacterial evaluation; determine need for CSF testing, antibiotics, and admission from the complete risk profile. [5][22] |
| Fever duration under 6 hours | Early biomarkers can be falsely reassuring. [4] | Observe or use a lower escalation threshold. [4] |

## Do not let a positive viral test replace bacterial testing

Viral positivity modifies pretest probability but does not eliminate coinfection.

Respiratory viral positivity is associated with lower prevalence of UTI, bacteremia, and meningitis in febrile young infants, but clinically important bacterial infection remains non-negligible. Continue age-appropriate urine and bacterial evaluation rather than using viral detection as a rule-out test. [1][2]

SARS-CoV-2-positive infants aged 8 to 60 days have lower prevalence of UTI, bacteremia, and meningitis than virus-negative infants, especially those aged 29 to 60 days with normal inflammatory markers. The most useful role of SARS-CoV-2 testing is therefore as a risk modifier after—not instead of—urinalysis and inflammatory-marker assessment. [2]

For infants aged 61 to 90 days, respiratory viral infection is also associated with lower UTI prevalence; reported UTI rates among influenza-, RSV-, or SARS-CoV-2-positive infants were 2.2% to 5.2%. That residual rate supports continued urine-focused assessment when clinical evaluation indicates UTI risk. [16]
- A viral-positive 29- to 60-day-old infant with normal inflammatory markers is lower risk than a viral-negative infant, but not automatically eligible for discharge. [2]
- A positive viral assay does not resolve an abnormal urinalysis, abnormal inflammatory markers, ill appearance, or very young age. [1][2][5]

*How respiratory viral results should change—not replace—febrile-infant evaluation. [1][2][16]*

| Viral result | Risk interpretation | Practical consequence |
| --- | --- | --- |
| SARS-CoV-2 positive, 8-60 days | Lower UTI, bacteremia, and meningitis prevalence than in SARS-CoV-2-negative infants. [2] | Continue urine and inflammatory-marker assessment; use results with age to determine lumbar puncture and disposition. [2] |
| Non-SARS-CoV-2 respiratory virus detected | Lower but non-negligible UTI and invasive bacterial infection risk. [1] | Do not omit bacterial evaluation solely because a respiratory virus is detected. [1] |
| Virus positive, 61-90 days | UTI prevalence remains 2.2%-5.2% for influenza, RSV, or SARS-CoV-2. [16] | Use viral testing as a probability modifier, not a substitute for urine testing. [16] |

## Select outpatient management only after documented low-risk assessment and observation

Outpatient care is a structured disposition decision, not simply a negative initial screen.

Prospective outpatient management without lumbar puncture or antibiotics has been reported for selected infants older than 21 days who were well appearing, had no urine leukocytes, ANC 10,000/mm3 or lower, CRP 20 mg/L or lower, procalcitonin below 0.5 ng/mL, and no clinical deterioration during an emergency stay of less than 24 hours. Among 586 such infants managed as outpatients, two had serious bacterial infection and no patient returned with an invasive bacterial infection. [22]

For U.S. practice, use the more stringent age-specific AAP-oriented framework for infants 29 to 60 days: normal urinalysis and reassuring inflammatory markers support avoiding lumbar puncture, empiric antibiotics, and hospitalization in selected patients, but the disposition requires reliable follow-up and a plan to act on culture results. [5][14]

Do not discharge based on normal early testing when the clinical trajectory is worsening. In the outpatient cohort, absence of deterioration during observation was an explicit low-risk requirement; in an external evaluation of Step-by-Step, an infant presenting within 6 hours of fever onset had normal urinalysis and biomarkers but Staphylococcus aureus bacteremia. [4][22]
- Observe before discharge when fever is early, the examination is evolving, or laboratory interpretation is borderline; clinical deterioration during observation excludes low-risk outpatient management. [4][22]
- Obtain blood and urine cultures before disposition whenever these tests are part of the selected pathway, then ensure a system for prompt review and response to positive culture results. [5][22]
- Avoid assuming that low-risk designation means zero invasive bacterial infection risk; communicate and document the follow-up contingency explicitly. [5]

*Disposition framework for well-appearing febrile infants. [4][5][13][22]*

| Disposition option | Supported selection features | Reason to avoid this option |
| --- | --- | --- |
| Hospital-based evaluation | Infant younger than 28 days or otherwise outside low-risk outpatient criteria. [13] | Do not use older-infant outpatient criteria in this age group. [13] |
| Potential outpatient management without lumbar puncture or antibiotics | Age older than 21 days; well appearance; absent urine leukocytes; ANC 10,000/mm3 or lower; CRP 20 mg/L or lower; procalcitonin below 0.5 ng/mL; no deterioration during observation. [22] | Abnormal urine or biomarkers, clinical deterioration, or inability to complete observation excludes this profile. [22] |
| Selected 29-60 day discharge under AAP-oriented risk stratification | Normal urinalysis and reassuring inflammatory markers identify substantially lower invasive bacterial infection risk. [5][14] | Risk remains nonzero; abnormal testing, evolving illness, or unreliable follow-up requires escalation. [5] |

## Common questions

### Can a positive SARS-CoV-2 test justify skipping urinalysis in a febrile infant?

No. SARS-CoV-2 positivity lowers the prevalence of UTI and invasive bacterial infection, particularly after 29 days with normal inflammatory markers, but does not eliminate bacterial coinfection; retain age-appropriate urine evaluation. [1][2]

### What should be done when procalcitonin is unavailable?

Use the combined temperature, ANC, and CRP strategy: abnormal values are temperature greater than 38.5°C, ANC greater than 5,200/mm3, and CRP 20 mg/L or greater. Do not use a single marker alone to classify an infant low risk. [14][20]

## References
1. Urinary Tract Infection, Bacteremia, and Meningitis Among Febrile Young Infants With SARS-CoV-2 and — jamanetwork.com — https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2806590
2. Prevalence of Urinary Tract Infection, Bacteremia, and Meningitis Among Febrile Infants Aged 8 to 60 Days With — jamanetwork.com — https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2804850
3. Viral bronchiolitis - The Lancet — www.thelancet.com — https://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(16)30951-5.pdf
4. Application of Step-by-Step and Paediatric Emergency Care Applied Research Network (PECARN) Clinical Decision Aids in the management of young febrile infants in a UK cohort | Emergency Medicine Journal — emj.bmj.com — https://emj.bmj.com/content/early/2025/10/06/emermed-2025-214876
5. Disparities and implicit bias in the management of low- risk febrile ... — bmjopen.bmj.com — https://bmjopen.bmj.com/content/bmjopen/12/9/e063611.full.pdf
6. Successful Outpatient Management of Febrile Infants Without a Lumbar Puncture or Antibiotics | NEJM Clinician — clinician.nejm.org — https://clinician.nejm.org/successful-outpatient-management-febrile-infants-without-lumbar-puncture-antibiotics-nejm-jw.NA43607
7. SAEM25 Abstracts - 2025 - Academic Emergency Medicine — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/10.1111/acem.70052?af=R
8. Risk of Meningitis in Infants Aged 29 to 90 Days with Urinary Tract Infection: A Systematic Review and Meta-Analysis - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0022347619305360
9. Risk of Urinary Tract Infection and Bacteremia in Infants... : Pediatric Emergency Care — journals.lww.com — https://journals.lww.com/pec-online/fulltext/2025/03000/risk_of_urinary_tract_infection_and_bacteremia_in.12.aspx
10. Frequency of serious bacterial infections in young infants with and without viral respiratory infections - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0735675721008068
11. Admit Versus Discharge—A Cost Analysis of Infants 29 to 60 Days Old With Febrile Urinary Tract Infection at Low Risk for Bacteremia - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1876285918307484
12. Abstracts of the European Academy of Paediatrics Congress and ... — onlinelibrary.wiley.com — https://onlinelibrary.wiley.com/doi/full/10.1111/apa.70432
13. Evaluation of the febrile infant younger than 3 months of age with no source of infection - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/0735675795900977
14. Guideline-Based Risk Stratification for Febrile Young Infants Without Procalcitonin Measurement | Pediatrics | American Academy of Pediatrics — publications.aap.org — https://publications.aap.org/pediatrics/article/149/6/e2021056028/188016/Guideline-Based-Risk-Stratification-for-Febrile
15. Rate of Urinary Tract Infections, Bacteremia, and Meningitis in Preterm and Term Infants | Pediatrics | American Academy of Pediatrics — publications.aap.org — https://publications.aap.org/pediatrics/article/153/4/e2023062755/196869/Rate-of-Urinary-Tract-Infections-Bacteremia-and
16. Risk of Bacterial Infections in Febrile Infants 61 to 90 Days Old With Respiratory Viruses | Pediatrics | American Academy of Pediatrics — publications.aap.org — https://publications.aap.org/pediatrics/article/156/1/e2025070617/202105/Risk-of-Bacterial-Infections-in-Febrile-Infants-61
17. Investigating the Role of Staphylococcal Biofilms in the Pathogenesis of Pediatric Atopic Dermatitis — www.jacionline.org — https://www.jacionline.org/pb/assets/raw/Health%20Advance/journals/ymai/2018_Saturday_March_3.pdf
18. Optimizing Management of Febrile Young Infants Without Serum ... — publications.aap.org — https://publications.aap.org/pediatrics/article/155/2/e2024068200/200541/Optimizing-Management-of-Febrile-Young-Infants
19. Use of Procalcitonin in a Febrile Infant Clinical Pathway and Impact on Infants Aged 29 to 60 Days - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC8287898
20. Ask the Expert-Management of the Well-Appearing Febrile Young ... — www.acep.org — https://www.acep.org/pediatrics/education/education-articles/ask-the-expert-article
21. Ask the Expert-Management of the Well-Appearing Febrile Young Infant: Integrating the AAP Guideline into Practice | Pediatric Emergency Medicine — acep.org — https://acep.org/pediatrics/education/education-articles/ask-the-expert-article
22. Outpatient management of selected young febrile infants without antibiotics - PubMed — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pubmed/27470162
23. Oluwole YESCARTA in the outpatient setting. 05SEP23 1 of 74 — cdn.clinicaltrials.gov — https://cdn.clinicaltrials.gov/large-docs/05/NCT05108805/Prot_SAP_001.pdf
24. [PDF] Preventing Adverse Incisional Outcomes at ... - ClinicalTrials.gov — cdn.clinicaltrials.gov — https://cdn.clinicaltrials.gov/large-docs/10/NCT03009110/Prot_SAP_000.pdf

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.